Company: PGEN
Filing Date: 2025-08-19
Form Type: S-3
Source: 0000950103-25-010472
Chunk: 31

Company: PRECIGEN, INC.
Filing Date: 2025-08-19
Form: S-3
Chunk 31
---
50 days of the corporation’s receipt of the acquiring person’s request to consider
the grant of voting rights to the shares acquired in the control share acquisition. If voting rights are not granted and the Company’s
Articles of Incorporation or Bylaws permit, the acquiring person’s shares may be repurchased by the corporation, at its option,
at a price per share equal to the acquiring person’s cost. Virginia law grants dissenters’ rights to any shareholder who objects
to a control share acquisition that is approved by a vote of disinterested shareholders and that gives the acquiring person control of
a majority of the corporation’s voting shares.

Our Articles of Incorporation provide that the
statutory provisions governing control share acquisitions do not apply to our Company; therefore, we are not subject to this provision.

Authorized but Unissued Shares

The authorized but unissued shares of Common Stock
and preferred stock are available for future issuance without shareholder approval, subject to any limitations imposed by the Nasdaq Stock
Market LLC listing rules. These additional shares may be used for a variety of corporate finance transactions, acquisitions, and employee
benefit plans. The existence of authorized but unissued and unreserved Common Stock and preferred stock could make it more difficult or
discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger, or otherwise.

Listing on the Nasdaq Global Select Market

Our Common Stock is listed on the Nasdaq Global
Select Market under the symbol “PGEN”. Our Preferred Stock is not currently listed on any securities exchange.

Transfer Agent and Registrar

The transfer agent and registrar for our Common
Stock and our Preferred Stock is Equiniti Trust Company, LLC.

<div align='center'>16

Selling Stockholders</div>

This prospectus relates to the offering by certain
of our stockholders, whom we refer to as the “selling stockholders,” of up to an aggregate of 143,809,489 shares of our Common
Stock and up to an aggregate of 79,000 shares of our Preferred Stock. The Preferred Stock and Warrants that the Common Stock underly were
issued on December 30, 2024 in connection with the Private Placement with the selling stockholders listed in the table below. The selling
stockholders agreed pursuant to the terms of the Registration Rights Agreement dated as of December 30, 2024 to cause us to use reasonable
best efforts to register the resale of shares of our Preferred Stock and Warrants that the Common Stock underly issued in connection